Eupraxia Pharmaceuticals is trading 7.28% down at $6.50, with no clear company-specific negative announcement, filing, earnings update, or analyst action identified overnight.

  • This compares with its August 19, 2026 close of $7.01.
  • Latest listed releases were positive RESOLVE trial symptom data on August 13 and second-quarter financial results on August 11.
  • Healthcare is stronger pre-market, while major indexes are modestly lower, leaving the catalyst unclear.